Approval · Notice of Compliance 1891 · 2003
PROVERA: Notice of Compliance 1891
Issued September 29, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1891
- Date
- September 29, 2003
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Progestin
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PROVERA | 00708917 | Cancelled Post Market |
| PROVERA | 00030937 | Cancelled Post Market |
| PROVERA | 00729973 | Cancelled Post Market |
| PROVERA | 00030945 | Cancelled Post Market |
| PROVERA PAK | 02010739 | Cancelled Post Market |
| PROVERA PAK | 02010933 | Cancelled Post Market |
Medicinal ingredients
- MEDROXYPROGESTERONE ACETATE 2.5 MG per TAB
- MEDROXYPROGESTERONE ACETATE 5 MG per TAB
- MEDROXYPROGESTERONE ACETATE 10 MG per TAB
- MEDROXYPROGESTERONE ACETATE 100 MG per TAB